Prevention of age-related macular degeneration
- PMID: 20862519
- PMCID: PMC3021198
- DOI: 10.1007/s10792-010-9397-5
Prevention of age-related macular degeneration
Abstract
Age-related macular degeneration (AMD) is one of the leading causes of blindness in the developed world. Although effective treatment modalities such as anti-VEGF treatment have been developed for neovascular AMD, there is still no effective treatment for geographical atrophy, and therefore the most cost-effective management of AMD is to start with prevention. This review looks at current evidence on preventive measures targeted at AMD. Modalities reviewed include (1) nutritional supplements such as the Age-Related Eye Disease Study (AREDS) formula, lutein and zeaxanthin, omega-3 fatty acid, and berry extracts, (2) lifestyle modifications, including smoking and body-mass-index, and (3) filtering sunlight, i.e. sunglasses and blue-blocking intraocular lenses. In summary, the only proven effective preventive measures are stopping smoking and the AREDS formula.
Similar articles
-
Lutein + zeaxanthin and omega-3 fatty acids for age-related macular degeneration: the Age-Related Eye Disease Study 2 (AREDS2) randomized clinical trial.JAMA. 2013 May 15;309(19):2005-15. doi: 10.1001/jama.2013.4997. JAMA. 2013. PMID: 23644932 Clinical Trial.
-
Secondary analyses of the effects of lutein/zeaxanthin on age-related macular degeneration progression: AREDS2 report No. 3.JAMA Ophthalmol. 2014 Feb;132(2):142-9. doi: 10.1001/jamaophthalmol.2013.7376. JAMA Ophthalmol. 2014. PMID: 24310343 Free PMC article. Clinical Trial.
-
Nutritional supplements for age-related macular degeneration.Curr Opin Ophthalmol. 2010 May;21(3):184-9. doi: 10.1097/ICU.0b013e32833866ee. Curr Opin Ophthalmol. 2010. PMID: 20216418 Free PMC article. Review.
-
Long-term Outcomes of Adding Lutein/Zeaxanthin and ω-3 Fatty Acids to the AREDS Supplements on Age-Related Macular Degeneration Progression: AREDS2 Report 28.JAMA Ophthalmol. 2022 Jul 1;140(7):692-698. doi: 10.1001/jamaophthalmol.2022.1640. JAMA Ophthalmol. 2022. PMID: 35653117 Free PMC article. Clinical Trial.
-
Age-related Eye Disease Study 2: perspectives, recommendations, and unanswered questions.Curr Opin Ophthalmol. 2014 May;25(3):186-90. doi: 10.1097/ICU.0000000000000046. Curr Opin Ophthalmol. 2014. PMID: 24614146 Free PMC article. Review.
Cited by
-
Superior Bioavailability of a Novel Lutein and Zeaxanthin Formulation in Healthy Human Subjects.Ophthalmol Ther. 2022 Aug;11(4):1463-1477. doi: 10.1007/s40123-022-00522-x. Epub 2022 May 18. Ophthalmol Ther. 2022. PMID: 35585428 Free PMC article.
-
Incidence of visual impairment over a 20-year period: the Beaver Dam Eye Study.Ophthalmology. 2013 Jun;120(6):1210-9. doi: 10.1016/j.ophtha.2012.11.041. Epub 2013 Mar 1. Ophthalmology. 2013. PMID: 23466270 Free PMC article.
-
The interactions between ARMS2, CFH, VEGF-A and environmental factors on the risk of age-related macular degeneration.Mol Vis. 2024 Oct 7;30:320-335. eCollection 2024. Mol Vis. 2024. PMID: 39959171 Free PMC article.
-
Design and Evaluating Psychometric Properties of the Eye Care Behaviors Assessment Instrument.Int J Prev Med. 2023 Mar 21;14:35. doi: 10.4103/ijpvm.ijpvm_181_22. eCollection 2023. Int J Prev Med. 2023. PMID: 37351061 Free PMC article.
-
Photoreceptor dysfunction in early and intermediate age-related macular degeneration assessed with mfERG and spectral domain OCT.Doc Ophthalmol. 2016 Feb;132(1):17-26. doi: 10.1007/s10633-016-9523-4. Epub 2016 Jan 11. Doc Ophthalmol. 2016. PMID: 26754967
References
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical